276 related articles for article (PubMed ID: 22375489)
21. Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma.
Bruno B; Sorasio R; Patriarca F; Montefusco V; Guidi S; Busca A; Scimé R; Console G; Milone G; Marotta G; Dominietto A; Giaccone L; Rotta M; Falda M; Bacigalupo A; Bosi A; Corradini P; Fanin R; Pollichieni S; Boccadoro M;
Eur J Haematol; 2007 Apr; 78(4):330-7. PubMed ID: 17331132
[TBL] [Abstract][Full Text] [Related]
22. [Multicenter report of nonmyeloablative allogeneic stem cell transplantation for hematologic diseases].
Ai HS; Huang XJ; Qiao ZH; Wang JM; Chen BA; Bai H; Shi BF; Liang YM; Sun WJ
Zhonghua Xue Ye Xue Za Zhi; 2009 Aug; 30(8):505-8. PubMed ID: 19954634
[TBL] [Abstract][Full Text] [Related]
23. [Allogeneic stem cell transplantation following non-myeloablative conditioning: favorable results in 21 high risk patients with hematological malignancies treated in the Utrecht University Medical Center, the Netherlands].
Petersen EJ; Lokhorst HL; Verdonck LF
Ned Tijdschr Geneeskd; 2003 Nov; 147(47):2328-32. PubMed ID: 14669540
[TBL] [Abstract][Full Text] [Related]
24. Nonmyeloablative and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation: a clinical review.
Pollack SM; O'Connor TP; Hashash J; Tabbara IA
Am J Clin Oncol; 2009 Dec; 32(6):618-28. PubMed ID: 19593085
[TBL] [Abstract][Full Text] [Related]
25. [Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005].
Faber E; Koza V; Vítek A; Mayer J; Sedlácek P; Zák P; Zapletalová J; Benesová K; Krejcová H; Steinerová K; Maresová I; Cetkovský P
Vnitr Lek; 2006 Dec; 52(12):1172-80. PubMed ID: 17299910
[TBL] [Abstract][Full Text] [Related]
26. A new minimally ablative stem cell transplantation procedure in high-risk patients not eligible for nonmyeloablative allogeneic bone marrow transplantation.
Shapira MY; Or R; Resnick IB; Bitan M; Ackerstein A; Samuel S; Elad S; Zilberman I; Miron S; Slavin S
Bone Marrow Transplant; 2003 Sep; 32(6):557-61. PubMed ID: 12953126
[TBL] [Abstract][Full Text] [Related]
27. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.
Nakamura R; Rodriguez R; Palmer J; Stein A; Naing A; Tsai N; Chang K; Slovak ML; Bhatia R; Spielberger R; Kogut N; Pullarkat V; Kirschbaum M; Forman SJ; O'Donnell MR
Bone Marrow Transplant; 2007 Nov; 40(9):843-50. PubMed ID: 17724447
[TBL] [Abstract][Full Text] [Related]
28. [Allogeneic hematopoietic stem-cell transplantation for hematological malignancies].
Michallet M; Dhedin N; Michallet AS
Bull Cancer; 2001 Sep; 88(9):908-26. PubMed ID: 11604365
[TBL] [Abstract][Full Text] [Related]
29. Treatment of chronic granulomatous disease with nonmyeloablative conditioning and a T-cell-depleted hematopoietic allograft.
Horwitz ME; Barrett AJ; Brown MR; Carter CS; Childs R; Gallin JI; Holland SM; Linton GF; Miller JA; Leitman SF; Read EJ; Malech HL
N Engl J Med; 2001 Mar; 344(12):881-8. PubMed ID: 11259721
[TBL] [Abstract][Full Text] [Related]
30. Methotrexate Reduces the Incidence of Severe Acute Graft-versus-Host Disease without Increasing the Risk of Relapse after Reduced-Intensity Allogeneic Stem Cell Transplantation from Unrelated Donors.
Vigouroux S; Tabrizi R; Melot C; Coiffard J; Lafarge X; Marit G; Bouabdallah K; Pigneux A; Leguay T; Dilhuydy MS; Schmitt A; Boiron JM; Milpied N
Biol Blood Marrow Transplant; 2011 Jan; 17(1):93-100. PubMed ID: 20601038
[TBL] [Abstract][Full Text] [Related]
31. [Effects of allogeneic hematopoietic stem cell transplantation with very-high-dose conditioning regimen for refractory leukemia].
Liu QF; Sun J; Xu D; Zhang Y; Fan ZP; Wei YQ; Meng FY; Zhou SY
Di Yi Jun Yi Da Xue Xue Bao; 2004 Oct; 24(10):1117-9. PubMed ID: 15485779
[TBL] [Abstract][Full Text] [Related]
32. Short Report: Engraftment of T-cell-depleted allogeneic haematopoietic stem cells using a reduced intensity conditioning regimen.
Craddock C; Bardy P; Kreiter S; Johnston R; Apperley J; Marks D; Huber C; Kolbe K; Goulding R; Lawler M; Goldman J; Hughes T; Derigs G
Br J Haematol; 2000 Dec; 111(3):797-800. PubMed ID: 11122140
[TBL] [Abstract][Full Text] [Related]
33. [Allogeneic hematopoietic cell transplantation in solid tumors].
Bay JO; Choufi B; Tournilhac O; Faucher C; Blaise D
Bull Cancer; 2001 Sep; 88(9):900-7. PubMed ID: 11604364
[TBL] [Abstract][Full Text] [Related]
34. Advantages and limitations of (non-)myeloablative allogeneic stem cell transplantation.
Huugen D; Schouten HC; Bos GM
Neth J Med; 2002 May; 60(4):162-9. PubMed ID: 12164394
[TBL] [Abstract][Full Text] [Related]
35. Low intensity regimens with allogeneic hematopoietic stem cell transplantation as treatment of hematologic neoplasia.
Carella AM; Giralt S; Slavin S
Haematologica; 2000 Mar; 85(3):304-13. PubMed ID: 10702821
[TBL] [Abstract][Full Text] [Related]
36. Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas.
Bishop MR; Hou JW; Wilson WH; Steinberg SM; Odom J; Castro K; Kasten-Sportes C; Gea-Banacloche J; Marchigiani D; Gress R; Fowler DH
Biol Blood Marrow Transplant; 2003 Mar; 9(3):162-9. PubMed ID: 12652466
[TBL] [Abstract][Full Text] [Related]
37. [Nonmyeloablative allogeneic hematopoietic stem cell transplantation: minitransplantation].
Machaczka M; Rucińska M; Skotnicki AB
Przegl Lek; 1999; 56(10):633-7. PubMed ID: 10695376
[TBL] [Abstract][Full Text] [Related]
38. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
[TBL] [Abstract][Full Text] [Related]
39. Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation.
Jabbour E; Rondon G; Anderlini P; Giralt SA; Couriel DR; Champlin RE; Khouri IF
Bone Marrow Transplant; 2007 Sep; 40(5):431-5. PubMed ID: 17603511
[TBL] [Abstract][Full Text] [Related]
40. [Reduced-intensity hematopoietic stem cell transplantation and donor lymphocyte infusions for chronic myeloid leukemia].
Ichinohe T; Ishikawa T
Nihon Rinsho; 2003 Sep; 61(9):1573-8. PubMed ID: 14515726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]